Sunday, June 17, 2018 6:52:08 AM
thank you for transcribing every testimony of the ASCO presentation!
https://twitter.com/KristynPower
Kristyn Power? @KristynPower 7 jun.
I'm unbelievably grateful to $NWBO for the treatment options offered to GBM patients. In addition to very encouraging interim results for patient survival, there are also significant quality of life advantages to their treatment. My Dad is the "60 year old man" in the article.
Larry Smith @SmithOnStocks
$NWBO Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO See the report at this link. https://smithonstocks.com/northwest-biotherapeutics-five-spectacular-patient-outcome-for-patients-treated-with-dcvax-l-as-reported-at-asco-nwbo-0-28-buy/ …
And thanks for the attention for this article: Can Immunotherapy Succeed in Glioblastoma?
Subscribe May 24, 2018, by NCI Staff
This post was updated on June 6, 2018.
“Another vaccine, DCVax-L, is currently being tested in a phase III trial of patients with glioblastoma whose tumors could be removed surgically. DCVax-L is a dendritic cell vaccine, meaning it uses immune cells known as dendritic cells, which are collected from patients and engineered to provoke an immune response against multiple proteins, or antigens, on tumors.
Preliminary data from the trial were recently published, but only included survival data for the entire population of patients in the trial, not by treatment group. According to a statement from Northwest Biotherapeutics, which makes the vaccine and funded the trial, another round of data collection from the trial is ongoing.
Dr. Sampson’s team at Duke, which developed rindopepimut, has been testing a dendritic cell vaccine...…."
https://www.cancer.gov/news-events/cancer-currents-blog/2018/immunotherapy-glioblastoma
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM